Tariffs Could Wipe Out 280E Relief for Cannabis Cultivators

Cannabis rescheduling may deliver tax relief with one hand while new tariff policies take it away with the other—at least for cultivators and manufacturers who rely on imported equipment and supplies.

Justin Leiby, director of the Cannabis Research Institute, argues that while rescheduling removes the punishing 280E tax penalty, the Trump administration's tariff regime will fundamentally reshape which cannabis businesses actually benefit. "Rescheduling removes a major structural penalty, but tariffs will reshape who captures the gains," Leiby wrote in an analysis published this week. "All else equal, dispensary-heavy companies may emerge as the primary beneficiaries."

The 280E provision of the tax code has prevented cannabis businesses from deducting ordinary business expenses, effectively imposing tax rates that can exceed 70% on gross income. Rescheduling cannabis from Schedule I to Schedule III would eliminate this burden—a change the industry has sought for decades.

But the timing couldn't be more complicated.

The Tariff Problem

Cannabis cultivators depend heavily on imported goods. Growing equipment, lighting systems, HVAC units, packaging materials, and extraction equipment often come from China and other countries now facing steep tariff increases. Some tariffs on Chinese goods have already reached 25%, with threats of higher rates ahead.

For cultivation and manufacturing operations, these costs hit hard. A grower investing in new LED lighting arrays or climate control systems could see equipment costs jump 20-30% overnight. Extractors purchasing stainless steel vessels and pumps face similar increases. These are capital-intensive businesses operating on thin margins even before tariffs entered the equation.

Retail dispensaries, by contrast, face minimal direct tariff exposure. Their largest costs—rent, labor, inventory—remain largely domestic. They'll capture the full benefit of 280E relief without offsetting increases in their cost structure.

Winners and Losers

The divergence creates a competitive imbalance within the industry. Vertically integrated companies with heavy cultivation and manufacturing footprints may see their 280E savings partially or fully eroded by higher input costs. Pure-play retailers could see profit margins expand significantly.

Leibly's analysis suggests the gap could be substantial. A cultivation operation might save $2 million annually from 280E relief but face $1.5 million in additional tariff-related costs. Meanwhile, a dispensary chain saving the same $2 million faces virtually no tariff impact.

The timing matters too. Rescheduling implementation remains uncertain—the DEA's final rule isn't expected until later this year at earliest. Tariffs, however, are already in effect or rapidly approaching. Some businesses may face the cost increases before seeing any tax relief.

Market Implications

The competitive dynamics could accelerate industry consolidation. Dispensary-focused MSOs may gain valuation advantages over cultivation-heavy operators, making them stronger acquisition candidates or acquirers. Companies may also rethink their vertical integration strategies, potentially divesting grow operations to focus on retail.

Some larger operators might absorb short-term pain by reshoring equipment manufacturing or finding domestic suppliers. But that takes time and capital—resources many cannabis companies lack after years of compressed margins under 280E.

Smaller cultivators face the toughest position. They can't easily absorb cost increases, lack leverage to negotiate better equipment pricing, and often can't afford to wait out tariff policy uncertainty.

What's Next

The industry now faces a dual policy environment it didn't anticipate. Rescheduling advocacy assumed tax relief would flow broadly across all license types. The tariff variable wasn't part of that calculation.

Trade associations may need to push for cannabis-specific tariff exemptions, though that faces long odds given the administration's protectionist stance. More likely, businesses will need to adapt their strategies—accelerating retail expansion, delaying cultivation upgrades, or accepting compressed margins as the new normal.

The DEA's final rescheduling rule will matter more than ever. If implementation drags into 2026, cultivators could face a full year or more of tariff pain before seeing any tax relief. That timeline could determine which companies survive the transition and which don't.

---

This article is based on original reporting by www.marijuanamoment.net.